Compare · DXCM vs IINN
DXCM vs IINN
Side-by-side comparison of DexCom Inc. (DXCM) and Inspira Technologies Oxy B.H.N. Ltd. (IINN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IINN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 1771.6x IINN ($16.7M).
- Over the past year, DXCM is down 8.7% and IINN is down 48.0% - DXCM leads by 39.3 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 17 for IINN).
- DXCM has more recent analyst coverage (25 ratings vs 2 for IINN).
- Company
- DexCom Inc.
- Inspira Technologies Oxy B.H.N. Ltd.
- Price
- $78.19+2.08%
- $0.38+0.51%
- Market cap
- $29.57B
- $16.7M
- 1M return
- +29.01%
- -34.36%
- 1Y return
- -8.70%
- -47.97%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 26
- 17
- Recent ratings
- 25
- 2
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest IINN
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Awarded Government Grant to Advance the World's First Native RF Dielectric Material for Quantum Computing
- SEC Form F-3 filed by Inspira Technologies Oxy B.H.N. Ltd.
- Chief Technology Officer Yechezkely Hayon Daniella sold $150,000 worth of Ordinary Shares (50,000 units at $3.00), decreasing direct ownership by 6% to 780,000 units (SEC Form 4)
- Chief Financial Officer Tehila Yafit sold $105,019 worth of Ordinary Shares (30,000 units at $3.50) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 870,000 units (SEC Form 4)
- COO and VP of R&D Shabtay Abraham exercised 95,239 units of Ordinary Shares at a strike of $3.37, increasing direct ownership by 8% to 1,332,713 units (SEC Form 4)
- QTREX to Showcase Functional AME-Based Monolithic Connectivity Components for Quantum Computing Systems at Quantum.Tech World 2026 in Boston
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Secures Purchase Order from a U.S.-based Fortune 500 company for an AME System and Related Materials